NCT00612105View on ClinicalTrials.gov

Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN)

PHASE2CompletedINTERVENTIONAL
Enrollment

187

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

May 31, 2009

Study Completion Date

December 31, 2009

Conditions
Postherpetic Neuralgia
Interventions
DRUG

Retigabine

150mg/day up to 900mg/day

DRUG

Placebo

daily

Trial Locations (45)

6001

Port Elizabeth

6529

George

7530

Belville

8755

Toms River

9300

Bloemfontein

10004

New York

15017

Bridgeville

18103

Allentown

27103

Winston-Salem

27607

Raleigh

28463

Tabor City

29412

Charleston

29566

Little River

29582

North Myrtle Beach

30308

Atlanta

30309

Atlanta

32806

Orlando

33407

West Palm Beach

33613

Tampa

34243

Sarasota

35215

Birmingham

37215

Nashville

39401

Hattiesburg

40503

Lexington

44195

Cleveland

44260

Mogadore

47714

Evansville

48201

Detroit

48706

Bay City

58104

Fargo

63117

St Louis

63141

St Louis

66211

Overland Park

71103

Shreveport

72205

Little Rock

77479

Sugar Land

78229

San Antonio

78756

Austin

85210

Mesa

85741

Tucson

91361

Westlake Village

92037

La Jolla

92128

San Diego

92845

Garden Grove

84047-1761

Midvale

All Listed Sponsors
lead

Bausch Health Americas, Inc.

INDUSTRY

NCT00612105 - Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN) | Biotech Hunter | Biotech Hunter